Geron Corp (GERN) | |||
---|---|---|---|
3.73 0.05 (1.36%) | 04-18 16:00 | ||
Open: | 3.71 | Pre. Close: | 3.68 |
High: | 3.87 | Low: | 3.6403 |
Volume: | 9,734,638 | Market Cap: | 2,193(M) |
Stock Technical Analysis | |
---|---|
Overall: | |
Target: | Six months: 4.73 One year: 5.53 |
Support: | Support1: 2.63 Support2: 1.75 |
Resistance: | Resistance1: 4.05 Resistance2: 4.73 |
Pivot: | 3.42 |
Moving Averages: | MA(5): 3.62 MA(20): 3.39 MA(100): 2.36 MA(250): 2.51 |
MACD: | MACD(12,26): 0.28 Signal(12,26,9): 0.28 |
%K %D: | %K(14,3): 61.33 %D(3): 54.67 |
RSI: | RSI(14): 67.10 |
52-Week: | High: 4.05 Low: 1.64 Change(%): 48.6 |
Average Vol(K): | 3-Month: 12914 10-Days: 11643 |
Prices Prediction (Update @5:00pm) | ||
---|---|---|
If tomorrow: | Open lower | Open higher |
High: | 3.876 - 3.891 | 3.891 - 3.908 |
Low: | 3.603 - 3.619 | 3.619 - 3.635 |
Close: | 3.704 - 3.732 | 3.732 - 3.76 |
Price, MAs and Bollinger Bands |
---|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ GERN ] has closed below upper band by 13.2%. Bollinger Bands are 21.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
Company profile |
---|
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California. |
Stock chart |
---|
Financial Analysis | |
---|---|
Price to Book Value: | Outperform |
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
Price to Earnings: | Underperform |
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
Discounted cash flow: | Underperform |
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
Return on Assets: | Underperform |
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
Return on Equity: | Underperform |
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
Debt to Equity: | Outperform |
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Stock Basics & Statistics | |
---|---|
Exchange: NASDAQ Global Select | |
Sector: Healthcare | |
Industry: Biotechnology | |
Shares Out. (M) | |
Shares Float (M) | 588.06 |
% Held by Insiders | 475070016.00 |
% Held by Institutions | 0.09 |
Shares Short (K) | 44910 |
Shares Short Prior Month (K) |
Stock Financials | |
---|---|
EPS | -193500000.000 |
Book Value (p.s.) | |
Profit Margin | |
Operating Margin | -236.00 |
Return on Assets (ttm) | 39.1 |
Return on Equity (ttm) | -41.5 |
Qtrly Rev. Growth | 237000.0 |
Gross Profit (p.s.) | -127.377 |
Sales Per Share | -184.082 |
EBITDA (p.s.) | |
Qtrly Earnings Growth | -0.32 |
Operating Cash Flow (M) | |
Levered Free Cash Flow (M) | -167.74 |
Stock Valuation | |
---|---|
PE Ratio | |
PEG Ratio | -2.28 |
Price to Book value | |
Price to Sales | -0.02 |
Price to Cash Flow | 4.95 |
Stock Dividends | |
---|---|
Dividend | |
Dividend Yield | |
Dividend Growth | 46660000.000 |